Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction
Abstract Aims The use of new psychoactive substances (NPS) has become increasingly widespread over the last decade, in Japan and internationally. NPS are associated with a range of increasingly serious clinical, public, and social issues. Political measures to ameliorate the effects of NPS in Japan...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-06-01
|
| Series: | Neuropsychopharmacology Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/npr2.12053 |
| _version_ | 1811301420825051136 |
|---|---|
| author | Daisuke Funada Toshihiko Matsumoto Yuko Tanibuchi Yasunari Kawasoe Satoru Sakakibara Nobuya Naruse Shunichiro Ikeda Takashi Sunami Takeo Muto Tetsuji Cho |
| author_facet | Daisuke Funada Toshihiko Matsumoto Yuko Tanibuchi Yasunari Kawasoe Satoru Sakakibara Nobuya Naruse Shunichiro Ikeda Takashi Sunami Takeo Muto Tetsuji Cho |
| author_sort | Daisuke Funada |
| collection | DOAJ |
| description | Abstract Aims The use of new psychoactive substances (NPS) has become increasingly widespread over the last decade, in Japan and internationally. NPS are associated with a range of increasingly serious clinical, public, and social issues. Political measures to ameliorate the effects of NPS in Japan have focused on tightening regulation rather than establishing treatment methods. The current study sought to compare the neuropsychiatric symptoms of patients with NPS‐related disorders across several years. We examined patients who attended specialized hospitals for treating addiction, to elucidate the impacts of legal measures to control NPS. Methods Subjects (n = 864) were patients with NPS‐related disorders who received medical treatment at eight specialized hospitals for treating addiction in Japan between April 2012 and March 2015. Clinical information was collected retrospectively from medical records. Results Among psychiatric symptoms, the ratio of hallucinations/delusions decreased over time across 3 years of study (first year vs second year vs third year: 40.1% vs 30.9% vs 31.7%, P = 0.037). Among neurological symptoms, the ratio of coma/syncope increased over the 3‐year period (7.8% vs 11.0% vs 17.0%, P = 0.002), as did the ratio of convulsions (2.8% vs 4.3% vs 9.7%, P = 0.001). Conclusion The symptoms associated with NPS were primarily psychiatric in the first year, while the prevalence of neurological symptoms increased each year. The risk of death and the severity of symptoms were greater in the third year compared with the first year, as regulation of NPS increased. |
| first_indexed | 2024-04-13T07:08:30Z |
| format | Article |
| id | doaj.art-faad6dca49594a6984bd5755f44daf33 |
| institution | Directory Open Access Journal |
| issn | 2574-173X |
| language | English |
| last_indexed | 2024-04-13T07:08:30Z |
| publishDate | 2019-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neuropsychopharmacology Reports |
| spelling | doaj.art-faad6dca49594a6984bd5755f44daf332022-12-22T02:56:57ZengWileyNeuropsychopharmacology Reports2574-173X2019-06-0139211912910.1002/npr2.12053Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addictionDaisuke Funada0Toshihiko Matsumoto1Yuko Tanibuchi2Yasunari Kawasoe3Satoru Sakakibara4Nobuya Naruse5Shunichiro Ikeda6Takashi Sunami7Takeo Muto8Tetsuji Cho9National Center of Neurology and Psychiatry National Center Hospital Kodaira JapanNational Center of Neurology and Psychiatry National Institute of Mental Health Kodaira JapanNational Center of Neurology and Psychiatry National Institute of Mental Health Kodaira JapanAsahi General Hospital Asahi JapanTokyo Metropolitan Matsuzawa Hospital Setagaya‐ku JapanSaitama Psychiatric Medical Center Inamachi JapanKansai Medical University Hirakatashi JapanOkayama Psychiatric Medical Center Kita‐ku JapanHizen Psychiatric Center Kanzaki‐gun JapanMie Prefectural Mental Medical Center Tsu JapanAbstract Aims The use of new psychoactive substances (NPS) has become increasingly widespread over the last decade, in Japan and internationally. NPS are associated with a range of increasingly serious clinical, public, and social issues. Political measures to ameliorate the effects of NPS in Japan have focused on tightening regulation rather than establishing treatment methods. The current study sought to compare the neuropsychiatric symptoms of patients with NPS‐related disorders across several years. We examined patients who attended specialized hospitals for treating addiction, to elucidate the impacts of legal measures to control NPS. Methods Subjects (n = 864) were patients with NPS‐related disorders who received medical treatment at eight specialized hospitals for treating addiction in Japan between April 2012 and March 2015. Clinical information was collected retrospectively from medical records. Results Among psychiatric symptoms, the ratio of hallucinations/delusions decreased over time across 3 years of study (first year vs second year vs third year: 40.1% vs 30.9% vs 31.7%, P = 0.037). Among neurological symptoms, the ratio of coma/syncope increased over the 3‐year period (7.8% vs 11.0% vs 17.0%, P = 0.002), as did the ratio of convulsions (2.8% vs 4.3% vs 9.7%, P = 0.001). Conclusion The symptoms associated with NPS were primarily psychiatric in the first year, while the prevalence of neurological symptoms increased each year. The risk of death and the severity of symptoms were greater in the third year compared with the first year, as regulation of NPS increased.https://doi.org/10.1002/npr2.12053addictiongovernment regulationnew psychoactive substancepsychiatric hospitalsubstance‐related disorders |
| spellingShingle | Daisuke Funada Toshihiko Matsumoto Yuko Tanibuchi Yasunari Kawasoe Satoru Sakakibara Nobuya Naruse Shunichiro Ikeda Takashi Sunami Takeo Muto Tetsuji Cho Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction Neuropsychopharmacology Reports addiction government regulation new psychoactive substance psychiatric hospital substance‐related disorders |
| title | Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction |
| title_full | Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction |
| title_fullStr | Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction |
| title_full_unstemmed | Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction |
| title_short | Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction |
| title_sort | changes of clinical symptoms in patients with new psychoactive substance nps related disorders from fiscal year 2012 to 2014 a study in hospitals specializing in the treatment of addiction |
| topic | addiction government regulation new psychoactive substance psychiatric hospital substance‐related disorders |
| url | https://doi.org/10.1002/npr2.12053 |
| work_keys_str_mv | AT daisukefunada changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction AT toshihikomatsumoto changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction AT yukotanibuchi changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction AT yasunarikawasoe changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction AT satorusakakibara changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction AT nobuyanaruse changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction AT shunichiroikeda changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction AT takashisunami changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction AT takeomuto changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction AT tetsujicho changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction |